Clinical Trials Logo
  1. Home
  2. Crohn's Disease
  3. NCT03890445

Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease — GIANT  

Crohn´s Disease Clinical Trial

Official title:
GIANT - A Multicenter, Prospective, Observational Study of Real-world Anti-TNFa Treatment Regimens of Hyrimoz™ (Adalimumab Biosimilar) or Zessly™ (Infliximab Biosimilar) in Patients With Crohn's Disease

Clinical Trial Summary

Hyrimoz™ was developed as a biosimilar to HumiraTM (INN: adalimumab) and Zessly™ was developed as a biosimilar to RemicadeTM (INN: infliximab). Within the Biosimilar Development Program of Hyrimoz™ and Zessly™, two clinical confirmatory efficacy and safety studies were conducted: Hyrimoz™ in plaque psoriasis and Zessly™ in rheumatoid arthritis. Both confirmatory Phase III studies demonstrated equivalent efficacy and similar safety and immunogenicity of Hyrimoz™ to HumiraTM and Zessly™ to RemicadeTM, respectively. The current study is designed to provide a systematic and consistent overview of the real-world data in biologic-naïve patients with moderate-to-severe Crohn's disease (CD). The data collected in this observational trial will be used to increase the knowledge of the effectiveness of Hyrimoz™ and Zessly™ in clinical routine care in patients with moderate-to-severe CD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03890445
Study type Observational
Source Sandoz
Contact
Status Completed
Phase
Start date June 24, 2019
Completion date May 8, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT01860651 - Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease N/A
Completed NCT01102855 - Endomicroscopy and Crohn´s Disease N/A
Completed NCT01279577 - Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease Phase 2
Completed NCT01086553 - 9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease Phase 3
Completed NCT02763293 - Osteopathy Non-manipulative in Patients With Crohn's Disease. N/A
Completed NCT01289366 - Endocytoscopy for in Vivo Determination of Mucosal Inflammatory Cells and Intestinal Disease Activity in Inflammatory Bowel Disease (IBD) N/A
Recruiting NCT06006039 - The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Disease.
Recruiting NCT04022083 - Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
Completed NCT01564823 - Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease Phase 3
Completed NCT01768858 - Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
Completed NCT01417715 - Endomicroscopy for Assessment of Mucosal Healing
Completed NCT01417702 - Endoscopy for Assessment of Mucosal Healing in IBD
Terminated NCT00862121 - A Study With Pentasa in Patients With Active Crohn's Disease Phase 3